Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

• Julia Krämer ,

  * E-mail: julia.kraemer@ukmuenster.de (JK); sven.meuth@ukmuenster.de (SGM)

  Affiliation Department of Neurology, Clinic of Neurology and Institute of Translational Neurology, Westfälische Wilhelms University, Münster, Germany

  http://orcid.org/0000-0003-2219-5593

  ⨯
• Jan-Gerd Tenberge,

  Affiliation Department of Neurology, Clinic of Neurology and Institute of Translational Neurology, Westfälische Wilhelms University, Münster, Germany

  ⨯
• Ingo Kleiter,

  Affiliation Department of Neurology, St. Josef-Hospital, Ruhr-University-Bochum, Bochum, Germany

  ⨯
• Wolfgang Gaissmaier,

  Affiliation Department of Psychology, University of Konstanz, Konstanz, Germany

  ⨯
• Tobias Ruck,

  Affiliation Department of Neurology, Clinic of Neurology and Institute of Translational Neurology, Westfälische Wilhelms University, Münster, Germany

  ⨯
• Christoph Heesen ,

  Contributed equally to this work with: Christoph Heesen, Sven G. Meuth

  Affiliation Department of Neurology, Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Sven G. Meuth

  Contributed equally to this work with: Christoph Heesen, Sven G. Meuth

  * E-mail: julia.kraemer@ukmuenster.de (JK); sven.meuth@ukmuenster.de (SGM)

  Affiliation Department of Neurology, Clinic of Neurology and Institute of Translational Neurology, Westfälische Wilhelms University, Münster, Germany

  ⨯